Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Cycling Considerations While BPC-157 does not appear to cause receptor desensitization in the same way some compounds do, periodic breaks remain standard practice
This is one reason why many peptide protocols do not necessarily require injections directly into painful or damaged tissues
Specifically, it produces no IGF-1 elevation (avoiding proliferative concerns), no negative impact on glucose metabolism (avoiding diabetes risk), no fluid retention or edema, and no concerning patterns of joint pain that can occur with growth hormone
The research-grade material supplied by Koi Peptides Canada is not authorized under the Food and Drugs Act for use in humans, is not the same as Egrifta or any approved tesamorelin drug product, and is not intended to diagnose, treat, cure, or prevent any disease
